A case of metachronous peripheral T-Cell non-Hodgkin lymphoma following chemotherapy for Hodgkin disease successfully treated with brentuximab vedotin.
Autor: | Meconi F; Department of Biomedicine and Prevention University Tor Vergata Rome Italy., Provenzano I; Department of Biomedicine and Prevention University Tor Vergata Rome Italy., Nasso D; Department of Biomedicine and Prevention University Tor Vergata Rome Italy., Mariotti B; Department of Biomedicine and Prevention University Tor Vergata Rome Italy., Pupo L; Department of Biomedicine and Prevention University Tor Vergata Rome Italy., Secchi R; Department of Biomedicine and Prevention University Tor Vergata Rome Italy., Cerretti R; Department of Biomedicine and Prevention University Tor Vergata Rome Italy., Lucia A; Anatomic Pathology Department of Biomedicine and Prevention University of Rome Tor Vergata Rome Italy., Arcese W; Department of Biomedicine and Prevention University Tor Vergata Rome Italy., Cantonetti M; Department of Biomedicine and Prevention University Tor Vergata Rome Italy. |
---|---|
Jazyk: | angličtina |
Zdroj: | Clinical case reports [Clin Case Rep] 2020 May 05; Vol. 8 (8), pp. 1353-1356. Date of Electronic Publication: 2020 May 05 (Print Publication: 2020). |
DOI: | 10.1002/ccr3.2898 |
Abstrakt: | Occasionally, non-Hodgkin lymphomas (NHL) occur simultaneously or subsequently to Hodgkin disease. We report on a case of a woman with Hodgkin lymphoma treated with ABVD, who developed 4 years later T-cell NHL with both nodal and extranodal involvement. Brentuximab vedotin could be an effective choice in treating metachronous T-cell NHL. Competing Interests: The authors declare that there is no conflict of interest regarding the publication of this paper. (© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.) |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |